Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Adamis Pharmaceuticals Corporation    ADMP

ADAMIS PHARMACEUTICALS CORPORATION

(ADMP)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

ADAMIS PHARMACEUTICALS CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)

10/02/2020 | 04:29pm EST

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On September 29, 2020, Adamis Pharmaceuticals Corporation (the "Company") received a notice from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") notifying the Company that for 30 consecutive business days, the closing bid price of the Company's common stock was below $1.00 per share, which is the minimum required closing bid price for continued listing on the Nasdaq Capital Market pursuant to Marketplace Rule 5550(a)(2). This notice has no immediate effect on the Company's Nasdaq listing or the trading of its common stock.

In accordance with Nasdaq Marketplace Rule and 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of notification, or until March 29, 2021, to regain compliance. If at any time before March 29, 2021, the bid price of the Company's common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved compliance with the minimum bid price requirement, and the matter would be resolved. The notice letter also disclosed that if the Company does not regain compliance within the initial compliance period, it may be eligible for an additional 180-day compliance period. To qualify for additional time, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice of a plan to cure the deficiency during the second compliance period. If the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days to regain compliance. However, if it appears to the staff of Nasdaq that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the staff would notify the Company that it will not be granted additional 180 days for compliance and will be subject to delisting at that time. In the event of such notification, the Company may appeal the staff's determination to delist its securities. There are no assurances that the Company will be able to regain compliance with the minimum bid price requirements or will otherwise be in compliance with other Nasdaq listing rules.

The Company intends to monitor the closing bid price for its common stock and will consider available strategies in an effort to satisfy the minimum bid price requirement.

2

© Edgar Online, source Glimpses

All news about ADAMIS PHARMACEUTICALS CORPORATION
11/17ADAMIS PHARMACEUTICALS : Receives a Complete Response Letter from the FDA Regard..
AQ
11/16ADAMIS PHARMACEUTICALS CORP : Other Events (form 8-K)
AQ
11/16ADAMIS PHARMACEUTICALS : Receives a Complete Response Letter from the FDA Regard..
AQ
11/16Adamis Pharmaceuticals Receives a Complete Response Letter from the FDA Regar..
GL
11/09ADAMIS : 3Q Earnings Snapshot
AQ
11/09ADAMIS PHARMACEUTICALS : Announces Third Quarter 2020 Financial Results and Busi..
AQ
11/09Adamis Pharmaceuticals Announces Third Quarter 2020 Financial Results and Bus..
GL
11/09ADAMIS PHARMACEUTICALS CORP : Results of Operations and Financial Condition (for..
AQ
11/09ADAMIS PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condi..
AQ
11/05ADAMIS PHARMACEUTICALS : Schedules Third Quarter 2020 Results Conference Call an..
AQ
More news
Financials (USD)
Sales 2020 18,3 M - -
Net income 2020 -33,9 M - -
Net Debt 2020 - - -
P/E ratio 2020 -0,99x
Yield 2020 -
Capitalization 41,2 M 41,2 M -
Capi. / Sales 2020 2,26x
Capi. / Sales 2021 1,62x
Nbr of Employees 151
Free-Float 98,6%
Chart ADAMIS PHARMACEUTICALS CORPORATION
Duration : Period :
Adamis Pharmaceuticals Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAMIS PHARMACEUTICALS CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price
Last Close Price 0,44 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Dennis J. Carlo President, Chief Executive Officer & Director
Richard C. Williams Chairman
Karen K. Daniels Vice President-Operations
Robert O. Hopkins Chief Financial Officer, Secretary & VP-Finance
Ronald B. Moss Chief Medical Officer
Sector and Competitors